Results 181 to 190 of about 34,967 (216)
Drugs of Today, 2007 There is a real and viable need in the anticoagulant arena for a safe, robust, effective oral anticoagulant drug that measures up to warfarin in providing protection against thrombosis and compares favorably (if not better) with regard to safety profile, without the need for routine and often cumbersome monitoring.
Puneet, Kakar +2 more
openaire +3 more sources
Rivaroxaban postmarketing risk of liver injury [PDF]
Journal of Hepatology, 2014 BACKGROUND: Rivaroxaban is an oral direct factor Xa inhibitor that has been marketed worldwide since 2008 for the primary and secondary prevention and treatment of thromboembolic disorders.
Gerd A Kullak-Ublick +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Journal of Otolaryngology, 2015
The objective of this case report is to increase awareness regarding a new category of drugs, new direct oral anticoagulants (specifically, rivaroxaban), which are increasingly being used instead of the more traditional vitamin K antagonists, to highlight the current recommendations for perioperative management of rivaroxaban, and to demonstrate a ...
Alok T, Saini +2 more
openaire +2 more sources
The objective of this case report is to increase awareness regarding a new category of drugs, new direct oral anticoagulants (specifically, rivaroxaban), which are increasingly being used instead of the more traditional vitamin K antagonists, to highlight the current recommendations for perioperative management of rivaroxaban, and to demonstrate a ...
Alok T, Saini +2 more
openaire +2 more sources